NASDAQ: REVBRevelation Biosciences Inc Stock
$0.86-0.02 (-2.27%)
Updated Nov 18, 2025
REVB Price
$0.86
Fair Value Price
N/A
Market Cap
$5.09M
52 Week Low
$0.84
52 Week High
$60.48
P/E
0.01x
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$10M
Beta
1.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
REVB Overview
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine REVB's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
REVB
Ranked#385 of 484
Ranked#385 of 484
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $6.72 | A | |
| $103.89 | A | |
| $15.50 | A |
Be the first to know about important REVB news, forecast changes, insider trades & much more!
REVB News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how REVB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
REVB was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
REVB is good value based on its earnings relative to its share price (0.01x), compared to the US market average (44.3x)
P/E vs Market Valuation
REVB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more REVB due diligence checks available for Premium users.
Valuation
REVB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.01x
Industry
281.78x
Market
44.3x
REVB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
REVB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
REVB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
5.15x
REVB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
REVB's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
REVB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.9M
Liabilities
$1.9M
Debt to equity
0.17
REVB's short-term assets ($12.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REVB's short-term assets ($12.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REVB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
REVB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$0.0
Financing
$9.1M
REVB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
REVB vs Biotech Stocks
Revelation Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.